Navigation Links
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Date:1/4/2012

FREMONT, Calif., Jan. 4, 2012 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION).  QPI-1007 exhibited no dose limiting toxicities up to and including the highest dose of 6 milligrams enabled in this study, which is the highest dose of synthetic siRNA tested in the clinic following intravitreal administration.  After 3 months of follow up, patients treated in the study by a single dose of QPI-1007 exhibited no further loss of visual acuity, whereas vision loss was observed in previous studies(1) in non-treated NAION patients with similar initial disease severity. With the exception of one patient whose vision remained stable, all patients exhibited letter gains compared to baseline at screening, with some patients gaining 3-lines or more by 3 months after treatment.

The ongoing Phase 1 open-label, dose-escalation study, which is being conducted in 22 sites in the USA and 6 sites in Israel, has enrolled a total of 38 patients in two strata: Stratum I was a dose-escalation safety study in patients who are legally blind secondary to chronic optic nerve atrophy or retinal degeneration and is fully enrolled; Stratum II was designed to further evaluate safety and to assess for potential biological activity of QPI-1007 in recent-onset NAION patients by monitoring changes in visual function  following drug administration.

In Stratum II, two cohorts of ten patients each were given a single intravitreal injection of one of two doses of QPI-1007. After one month of follow-up, 40% of patients in Cohort 1 and 60% of patients in Cohort 2 gained 3 or more lines of visual acuity. At
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... (OMX Nordic: ACTI) presented,pre-clinical results for the ... League Against Rheumatism, <a target="_blank" href=,"http://www.eular.org/">www.eular.org ... data presented show that I-3D has a,significant ... model for rheumatoid arthritis (RA)", commented Sven,Andréasson, ...
... /PRNewswire/ -- Solstice,Neurosciences, Inc. today reported important results ... Toxin Type B,Injectable Solution (Myobloc(R)) recently presented at ... in,Istanbul, Turkey. , This was the first multicenter ... treatment doses of 10,000 Units, 12,500,Units, and 15,000 ...
Cached Medicine Technology:New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 2Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 3Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 4
(Date:7/10/2014)... more likely to be diagnosed with more aggressive ... for shorter times than prostate cancer patients who ... , The negative outcomes may be the result ... mentally ill, depression,s impact on biological cancer processes, ... general health and disinterest in receiving more effective ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to talk ... their silent suffering if they are willing to ... Baylor University case study., After seven weeks of hypnotic ... flashes following prostate cancer surgery showed a drastic decrease ... improvement in sleep quality, according to the study., The ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
Breaking Medicine News(10 mins):Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Urban Aboriginal people face unique health challenges 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
... pulmonary disorder is widespread but can be prevented , FRIDAY, ... for the diagnosis, management and prevention of a widespread, deadly ... affects 15 percent to 25 percent of adults over the ... death in the United States. It,s expected to become the ...
... Sept. 14 Aid provided by,The Prem Rawat Foundation ... women and their families who were victims of the ... After the flooding, caused by cyclones in this area ... displaced from their homes. The,Prem Rawat Foundation made a ...
... NNN Healthcare/Office REIT,Inc. has acquired 2750 Monroe ... September 10, 2007. 2750 Monroe Boulevard is ... feet, as well as an accessory building used,for ... on a 10.5-acre parcel,in the Valley Forge Corporate ...
... Va., Sept. 14 AMERIGROUP,Corporation (NYSE: AGP ) ... The event will be held at the Grand Hyatt ... presentations with the AMERIGROUP management team,beginning at 8:30 a.m. ... Frieden, who is Convener of,AMERIGROUP,s National Advisory Board on ...
... Company,(Nasdaq: PRGO ; TASE) today announced that President ... will provide a review of the Company,business for the ... a.m. EST in New York. The meeting will ... http://www.perrigo.com or by phone at 866-383-5538, participant,code ...
... fewer serious birth defects, U.S. experts say , , FRIDAY, Sept. ... increased among American women since the federal government mandated folate ... how much folate is enough -- or too much. , ... and Prevention (CDC) finds that the number of women of ...
Cached Medicine News:Health News:Experts Publish New Lung Disease Guidelines 2Health News:The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique 2Health News:NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania 2Health News:NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania 3Health News:AMERIGROUP Corporation to Host Investor Day 2Health News:Perrigo Company to Host Analyst Meeting on September 18, 2007 2Health News:Women's Folic Acid Levels Improving 2Health News:Women's Folic Acid Levels Improving 3Health News:Women's Folic Acid Levels Improving 4
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
... Medtronic presents the Streamline family of temporary ... taken the gold standard in temporary pacing ... make them easy to use and less ... 6491 Unipolar Pediatric Temporary Pacing Lead is ...
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: